Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer. 2023

Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.

Background: Lung cancer is associated with a high mortality rate and often complicated with malignant pleural effusion (MPE), which has a very poor clinical outcome with a short life expectancy. However, our understanding of cell-specific mechanisms underlying the pathobiology of pleural metastasis remains incomplete. Methods: We analyzed single-cell transcriptomes of cells in pleural effusion collected from patients with lung cancer and congestive heart failure (as a control), respectively. Soluble and complement factors were measured using a multiplex cytokine bead assay. The role of ferroptosis was evaluated by GPX4 small interfering RNA (siRNA) transfection and overexpression. Results: We found that the mesothelial-mesenchymal transition (MesoMT) of the pleural mesothelial cells contributed to pleural metastasis, which was validated by lung cancer/mesothelial cell co-culture experiments. The ferroptosis resistance that protected cancer from death which was secondary to extracellular matrix detachment was critical for pleural metastasis. We found a universal presence of immune-suppressive lipid-associated tumor-associated macrophages (LA-TAMs) with complement cascade alteration in the MPE of the lung cancer patients. Specifically, upregulated complement factors were also found in the MPE, and C5 was associated with poor overall survival in the lung cancer patients with epidermal growth factor receptor mutation. Plasmacytoid dendritic cells (pDCs) exhibited a dysfunctional phenotype and pro-tumorigenic feature in the primary cancer. High expression of the gene set extracted from pDCs was associated with a poor prognosis in the lung cancer patients. Receptor-ligand interaction analysis revealed that the pleural metastatic niche was aggravated by cross-talk between mesothelial cells-cancer cells/immune cells via TNC and ICAM1. Conclusions: Taken together, our results highlight cell-specific mechanisms involved in the pathobiological development of pleural metastasis in lung cancer. These results provide a large-scale and high-dimensional characterization of the pleural microenvironment and offer a useful resource for the future development of therapeutic drugs in lung cancer.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017423 Sequence Analysis, RNA A multistage process that includes cloning, physical mapping, subcloning, sequencing, and information analysis of an RNA SEQUENCE. RNA Sequence Analysis,Sequence Determination, RNA,Analysis, RNA Sequence,Determination, RNA Sequence,Determinations, RNA Sequence,RNA Sequence Determination,RNA Sequence Determinations,RNA Sequencing,Sequence Determinations, RNA,Analyses, RNA Sequence,RNA Sequence Analyses,Sequence Analyses, RNA,Sequencing, RNA
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D063646 Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years. Tumorigenesis,Oncogenesis,Carcinogeneses,Oncogeneses,Tumorigeneses
D066246 ErbB Receptors A family of structurally related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS. EGF Receptor,Epidermal Growth Factor Receptor,Epidermal Growth Factor Receptor Family Protein,Epidermal Growth Factor Receptor Protein-Tyrosine Kinase,ErbB Receptor,HER Family Receptor,Receptor, EGF,Receptor, Epidermal Growth Factor,Receptor, TGF-alpha,Receptor, Transforming-Growth Factor alpha,Receptor, Urogastrone,Receptors, Epidermal Growth Factor-Urogastrone,TGF-alpha Receptor,Transforming Growth Factor alpha Receptor,Urogastrone Receptor,c-erbB-1 Protein,erbB-1 Proto-Oncogene Protein,EGF Receptors,Epidermal Growth Factor Receptor Family Proteins,Epidermal Growth Factor Receptor Kinase,HER Family Receptors,Proto-oncogene c-ErbB-1 Protein,Receptor Tyrosine-protein Kinase erbB-1,Receptor, ErbB-1,Receptors, Epidermal Growth Factor,Epidermal Growth Factor Receptor Protein Tyrosine Kinase,ErbB-1 Receptor,Family Receptor, HER,Family Receptors, HER,Proto oncogene c ErbB 1 Protein,Proto-Oncogene Protein, erbB-1,Receptor Tyrosine protein Kinase erbB 1,Receptor, ErbB,Receptor, ErbB 1,Receptor, HER Family,Receptor, TGF alpha,Receptor, Transforming Growth Factor alpha,Receptors, EGF,Receptors, Epidermal Growth Factor Urogastrone,Receptors, ErbB,Receptors, HER Family,c erbB 1 Protein,c-ErbB-1 Protein, Proto-oncogene,erbB 1 Proto Oncogene Protein

Related Publications

Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
January 2024, Thoracic cancer,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
January 2022, Nature communications,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
January 2024, Therapeutic advances in medical oncology,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
September 2023, Translational lung cancer research,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
January 2021, Frontiers in immunology,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
December 2022, Clinical & experimental metastasis,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
June 2022, International journal of molecular sciences,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
October 2021, ESMO open,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
January 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,
Yu-Yuan Wu, and Ya-Ling Hsu, and Yung-Chi Huang, and Yue-Chiu Su, and Kuan-Li Wu, and Chao-Yuan Chang, and Chai-Tung Ong, and Jia-Chen Lai, and Tzu-Yen Shen, and Tai-Huang Lee, and Jen-Yu Hung, and Ying-Ming Tsai
May 2023, bioRxiv : the preprint server for biology,
Copied contents to your clipboard!